CAR T-Cell Therapy Recipient Surpasses 3-Year Cancer-Free Mark

July 21, 2021 by UChicago Medicine

Even three years later, Andrew Parker and his University of Chicago Medicine oncologist, Michael Bishop, MD, remain awed by the remarkable turnaround they witnessed thanks to CAR T-cell therapy.

In 2016, Parker, then 59, went to his primary care physician about a swollen leg and was stunned to learn he had aggressive acute lymphoblastic leukemia (ALL). The Michigan resident started an array of chemotherapy treatments, but none worked.

His health was quickly deteriorating.

His medical team suggested he contact Bishop, who was leading a clinical trial on an emerging cancer immunotherapy treatment called CAR T-cell therapy.

“They told me Dr. Bishop had something new,” Parker said. “I decided to do it. I had no choice.”

CAR T-cell therapy uses re-engineered versions of a patient’s own T-cells to find tumor cells and destroy them with minimal damage to healthy cells.

Parker qualified for the trial, but days before the process was scheduled to start, Bishop gave Parker some disappointing news.

“We can’t do it,” Bishop told him. The Food and Drug Administration (FDA) had put CAR-T treatments on hold.

Devastated, Parker returned home to Michigan believing he didn’t have much longer to live.

Bishop, meanwhile, appealed to the FDA, asking the agency to consider Parker for CAR T-cell therapy as a “compassionate use” because of the seriousness of his condition. The FDA gave Bishop the green light.

“A week later, Dr. Bishop called and said, ‘Come back! We can start!” Parker said.

Parker completed the CAR T-cell therapy treatment. As expected, he was sick for a few days and needed to be monitored in the intensive care unit. But by the third day, he felt fine.

A few weeks later, a bone marrow biopsy showed no cancer cells. Parker’s own T-cells had killed the cancer.

Since the 2016 treatment, the FDA has approved CAR T-cell therapy for use with certain types of leukemia and lymphoma. UChicago Medicine currently has 15 clinical trials for CAR T-cell therapy for different cancers, including multiple myeloma.

Within three months, Parker was healthy enough to return to his job as corporate manager of a tool and die shop. Today, the 61-year-old is back to his normal life — working, traveling, and enjoying life with his fiancé, Mary, who he calls his pillar of support during his cancer battle.

“It’s like a miracle,” Parker said.

Today, Parker gets regular infusions of immunoglobulin to protect him from infections and illness. A weakened immune system is a side effect of CAR T-cell therapy.

Every six months, he makes the seven-hour round-trip drive for a 15-minute appointment with Dr. Bishop, part of his clinical trial commitment.

“I see Dr. Bishop, give some blood, and then go home,” he said. “It’s worth every mile.”


UChicago Medicine is one of America’s leading academic medical institutions. It comprises the Pritzker School of Medicine, one of the top medical schools in the nation; the University of Chicago Biological Sciences Division, which twelve Noble Prize winners in physiology or medicine have been affiliated with; and the University of Chicago Medical Center, which recently opened the Center for Care and Discovery, a $700 million, 10-story specialty medical facility that focuses on cancer, digestive diseases, neurosciences, advanced surgery, and high-tech medical imaging. 

UChicago Medicine has 1,300 licensed beds, nearly 1,300 attending physicians, about 2,800 nurses and 1,000 residents and fellows, and offers a full range of specialty-care services for adults and children through more than 40 institutes and centers including an NCI-designated Comprehensive Cancer Center. 9 adult specialties and 2 children’s specialties are ranked nationally by US News and World Report. 

We are committed to providing the best treatment options as well as personalized services for Chinese patients who come to UChicago Medicine. We are also dedicated to bringing best practices to China and supporting our strategic partners to improve clinical quality and operational effectiveness through tailored consulting and/or training programs. 

About MORE Health

MORE Health, a global digital health company, provides peace of mind and confidence to patients when they need it most—when facing a serious life-changing illness. Delivering second medical opinions virtually, MORE Health delivers a diagnosis and recommended treatment plan from the world’s best medical minds. This collaborative approach to diagnosis puts the patient at the center of the process—empowering them to make informed decisions regarding their healthcare. Offering all the benefits of a second opinion, the service ensures that the attending doctor and the expert physician specialist are aligned through their proprietary, GDPR- and HIPAA-compliant Physician Collaboration Platform™, thus minimizing errors while also resolving potential conflicts regarding the diagnosis and treatment plan developed. Since 2013, MORE Health has helped patients on six continents and continues its mission to provide clients and their members access to the best medical minds in the world—when they need it most. Offered as an employee benefit or on an individual basis

Request a Demo
Social Wall